Blood Tests for Colorectal Cancer Screening in the Standard Risk Population

Current Colorectal Cancer Reports

Volumn 11, Issue 6, 2015, Pages 397-407

  Symonds, Erin L ^a,b   Young, Graeme P ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

Biomarkers; Colorectal cancer; Diagnosis; DNA; Early detection; Evaluation; Fecal immunochemical test; Methylation; MicroRNA; Participation; Prevention; Protein; RNA; Screening

Indexed keywords

ALPHA LEVO FUCOSIDASE; BIOLOGICAL MARKER; BMI1 PROTEIN; CARCINOEMBRYONIC ANTIGEN; DIPEPTIDYL PEPTIDASE IV; FERRITIN; K RAS PROTEIN; MICRORNA; MICRORNA 1246; MICRORNA 21; MICRORNA 23; OSTEOPONTIN; PROTEIN P53; SEPRASE; SEPTIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; EARLY DIAGNOSIS; FECES ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MARKER GENE; OCCULT BLOOD TEST; POPULATION RISK; PROTEOMICS; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY;

EID: 84947863079     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-015-0293-2     Document Type: Review

References (102)

1. AIHW. Cancer in Australia: an overview, 2014. Canberra: Australian Institute of Health and Welfare Canberra; 2014.
2. Martens JW et al. DNA methylation as a biomarker in breast cancer. Future Oncol. 2009;5(8):1245–56.
3. Osborne J et al. Sample preference for colorectal cancer screening tests: blood or stool? OJPM. 2012;2:326–31.
4. Weber H. Nachweis des blutes in dem magen- und dem darminhalt. Berl Klin Wochenachr. 1893;30:441.
5. Gurling KJ. The occult blood test. Postgrad Med J. 1951;27(309):345–8.
6. Illingworth DG. The choice of occult blood tests in general practice. J Coll Gen Pract. 1965;9:33–44.
7. Needham CD, Simpson RG. The benzidine test for occult blood in faces. Q J Med. 1952;21(82):123–33.
8. Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med. 2006;144(11):850–5. This study establishes the importance of sensitivity and specificity for diagnostic tests and what processes of validation are necessary.
9. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65(4):281–393.
10. Pepe MS et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93(14):1054–61. A key publication in describing the essential phases in developing and applying new screening tests for cancer.
11. World Gastroenterology News. W.G. Organisation; 2009.
12. Imperiale TF et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–97.
13. Johnson DA et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. PLoS One. 2014;9(6):e98238. This study demonstrates the phase 2 evaluation of a blood test biomarker (Septin9) and compares it to an established screening test (fecal immunochemical test).
14. Allison JE et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99(19):1462–70.
15. Levi Z et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128(10):2415–24.
16. Park DI et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105(9):2017–25.
17. Smith A et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer. 2006;107:2152–9.
18. Steele RJ et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol J. 2013;1(3):198–205.
19. Young GP, et al. Advances in fecal occult blood tests: the FIT Revolution. Dig Dis Sci. 2014.
20. Rabeneck L et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012;26(3):131–47.
21. Stracci F, Zorzi M, Grazzini G. Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health. 2014;2:210.
22. Hardcastle JD et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472–7.
23. Holme O et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312(6):606–15.
24. Kronborg O et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467–71.
25. Mandel JS et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365–71.
26. Elmunzer BJ et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2012;9(12):e1001352.
27. Mandel JS et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603–7.
28. Cole SR et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198(6):327–30.
29. OECD. Health at a Glance: Europe 2012. OECD Publishing; 2012. doi:10.1787/9789264183896-en.
30. AIHW. National Bowel Cancer Screening Program monitoring report: 2012–13. Vol. Cancer series No. 84. Canberra: Australian Institute of Health and Welfare Canberra; 2014.
31. Wee CC, McCarthy EP, Phillips RS. Factors associated with colon cancer screening: the role of patient factors and physician counseling. Prev Med. 2005;41(1):23–9.
32. Worthley DL et al. Screening for colorectal cancer by faecal occult blood test: why people choose to refuse. Intern Med J. 2006;36(9):607–10.
33. Cole SR et al. Psychosocial variables associated with colorectal cancer screening in South Australia. Int J Behav Med. 2011;18(4):302–9.
34. Adler A et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14:183.
35. Marshall DA et al. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health. 2007;10(5):415–30.
36. Silva JM et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut. 2002;50(4):530–4.
37. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2007;16(10):1935–53.
38. Walgenbach-Brunagel G et al. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. J Cell Biochem. 2008;104(1):286–94.
39. Bosch LJ et al. Molecular tests for colorectal cancer screening. Clin Colorectal Cancer. 2011;10(1):8–23.
40. Wong SC et al. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res. 2004;10(5):1613–7.
41. Perrone F et al. Circulating free DNA in a screening program for early colorectal cancer detection. Tumori. 2014;100(2):115–21.
42. Zhang X et al. Direct serum assay for cell-free bmi-1 mRNA and its potential diagnostic and prognostic value for colorectal cancer. Clin Cancer Res. 2015;21(5):1225–33.
43. Church TR et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63(2):317–25. A thorough study which assesses the performance of the blood biomarker Septin9 in a screening population. It has many characteristics of phase 3 evaluation with the exception that it is not an intention-to-screen study and so does not factor in acceptability.
44. Potter NT et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. Clin Chem. 2014;60(9):1183–91.
45. Pedersen S, et al. Evaluation of an assay for methylated 1 BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer. 2015; In press.
46. De Chiara L et al. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer. 2010;10:333.
47. Otero-Estevez O et al. Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test. Br J Cancer. 2015;112(2):375–81.
48. Ritchie SA et al. Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer. Int J Cancer. 2013;132(2):355–62.
49. Wild N et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16(24):6111–21.
50. Ng EK et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375–81.
51. Ardalan Khales S et al. SALL4 as a new biomarker for early colorectal cancers. J Cancer Res Clin Oncol. 2015;141(2):229–35.
52. Schiedeck TH et al. Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis Colon Rectum. 2003;46(6):818–25.
53. Terrin L et al. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res. 2008;14(22):7444–51.
54. Wang JY et al. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis. World J Surg. 2006;30(6):1007–13.
55. Yadegarazari R et al. Improved real-time rt-PCR assays of two colorectal cancer peripheral blood mRNA biomarkers: a pilot study. Iran Biomed J. 2013;17(1):15–21.
56. Lledo SM et al. Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Color Dis. 2004;6(4):236–42.
57. Wang Q et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012;7(9):e44398.
58. Chen X et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.
59. Toiyama Y et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59.
60. Ogata-Kawata H et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9(4):e92921.
61. Wang J et al. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One. 2014;9(4):e87451.
62. Stroun M et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987;23(6):707–12.
63. Jahr S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–65.
64. Danese E et al. Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med. 2010;48(11):1665–8.
65. Frigola J et al. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006;38(5):540–9.
66. Lee BB et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009;15(19):6185–91.
67. Lofton-Day C et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem. 2008;54(2):414–23.
68. Melnikov AA et al. Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol. 2009;99(2):119–22.
69. Van der Auwera I et al. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer. 2009;100(8):1277–86.
70. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004;4(9):707–17.
71. Esteller M. Cancer epigenetics for the 21st century: what’s next? Genes Cancer. 2011;2(6):604–6.
72. deVos T et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55(7):1337–46.
73. Guzzetta AA et al. The promise of methylation on beads for cancer detection and treatment. Expert Rev Mol Diagn. 2014;14(7):845–52.
74. Mitchell SM, et al. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer. 2014; In Press.
75. Phalguni A et al. Tests detecting biomarkers for screening of colorectal cancer: what is on the horizon? GMS Health Technol Assess. 2015;11:Doc01.
76. Fox A, Tietze PH, Ramakrishnan K. Anorectal conditions: hemorrhoids. FP Essent. 2014;419:11–9.
77. Symonds E et al. A methylated DNA blood test for colorectal cancer screening returns a lower false positivity rate than a faecal immunochemical test in people with benign bleeding conditions. J Gastroenterol Hepatol. 2014;29 Suppl 2:S130.
78. Thomson DM et al. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci U S A. 1969;64(1):161–7.
79. Bresalier RS, Kopetz S, Brenner DE. Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test? Dig Dis Sci. 2015;60(3):664–71.
80. Kim HJ et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res. 2009;8(3):1368–79.
81. Nishiumi S et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One. 2012;7(7):e40459.
82. Cordero OJ et al. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 2000;83(9):1139–46.
83. Ayude D et al. Value of the serum alpha-L-fucosidase activity in the diagnosis of colorectal cancer. Oncology. 2000;59(4):310–6.
84. Lee JH et al. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening. Int J Cancer. 2014;134(8):1844–53.
85. Zheng GX et al. Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. Exp Oncol. 2006;28(4):282–7.
86. Bennett KL et al. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res. 2008;68(12):4494–9.
87. Gilad R et al. High SEPT9_i1 protein expression is associated with high-grade prostate cancers. PLoS One. 2015;10(4):e0124251.
88. Lee HS et al. Circulating methylated septin 9 nucleic acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Transl Oncol. 2013;6(3):290–6.
89. Powrozek T et al. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol. 2014;31(4):917.
90. Ahlquist DA. Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci. 2015;60(3):623–33.
91. Levin B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130–60.
92. Haug U et al. Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection. Int J Cancer. 2015;136(12):2864–74.
93. Howlader N, et al. SEER cancer statistics review, 1975-2012. In: N.C. Institute, editor. Bethesda; 2013.
94. Kuntz KM et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Mak. 2011;31(4):530–9.
95. Subramanian S et al. Adherence with colorectal cancer screening guidelines: a review. Prev Med. 2004;38(5):536–50.
96. Cole SR et al. Predictors of re-participation in faecal occult blood test- based screening for colorectal cancer. Asian Pac J Cancer Prev. 2012;13(12):5989–94.
97. McClean HL, Taylor AJ, Mortimer AM. Fear of venepuncture as a barrier to testing for blood-borne infection and use of an oral fluid test as an alternative to venepuncture in a genitourinary medicine clinic. Sex Transm Infect. 2007;83(1):66–7.
98. Pfeffer N, Laws S. ‘It’s only a blood test’: what people know and think about venepuncture and blood. Soc Sci Med. 2006;62(12):3011–23.
99. Ahmed FE et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics. 2012;9(4):179–92.
100. Ladabaum U et al. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies. Cancer Epidemiol Biomarkers Prev. 2013;22(9):1567–76.
101. O’Halloran J, et al. Older patients attending general practice in Australia 2000–02. In: A.I.o.H.a. Welfare, editor. Canberra: Australian Institute of Health and Welfare Canberra; 2003.
102. Cole SR et al. Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner. J Med Screen. 2002;9(4):147–52.